Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodger L Bick

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 4, 2008
Reduced immunogenic potential of membrane filtered bovine thrombin preparations for hemostatic applicationHe Zhu, Debra Hoppensteadt, Rakesh Wahi, et al.
Hematology/Oncology Clinics of North America|January 22, 2008
Laboratory evaluation of the antiphospholipid syndromeDebra A Hoppensteadt, Nancy Fabbrini, Rodger L Bick, et al.
Hematology/Oncology Clinics of North America|January 11, 2005
Development of generic low molecular weight heparins: a perspectiveJawed Fareed, Wendy Leong, Debra A Hoppensteadt, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 26, 2005
Generic low molecular weight heparins: a significant dilemmaJawed Fareed, Omer Iqbal, Helena Nader, et al.
Seminars in Thrombosis and Hemostasis|April 16, 2004
Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosisJawed Fareed, Qing Ma, Michelle Florian, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|April 26, 2007
Potential thrombogenic complications with the use of recombinant activated factor VII in combat traumaJawed Fareed, Rodger L Bick, Craig Kessler, et al.
Expert Opinion on Investigational Drugs|February 28, 2002
Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agentJeanine M Walenga, Walter P Jeske, M Michel Samama, et al.
Seminars in Thrombosis and Hemostasis|January 5, 2005
Generic low-molecular-weight heparins: some practical considerationsJawed Fareed, Wendy L Leong, Debra A Hoppensteadt, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 9, 2006
Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implicationsJyothi Maddineni, Jeanine M Walenga, Walter P Jeske, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 10, 2008
The immunogenic potential of generic version of low-molecular-weight heparins may not be the same as the branded productsJawed Fareed, Rodger L Bick, Gundu Rao, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 4, 2008
Reduced immunogenic potential of membrane filtered bovine thrombin preparations for hemostatic applicationHe Zhu, Debra Hoppensteadt, Rakesh Wahi, et al.
Hematology/Oncology Clinics of North America|January 22, 2008
Laboratory evaluation of the antiphospholipid syndromeDebra A Hoppensteadt, Nancy Fabbrini, Rodger L Bick, et al.
Hematology/Oncology Clinics of North America|January 11, 2005
Development of generic low molecular weight heparins: a perspectiveJawed Fareed, Wendy Leong, Debra A Hoppensteadt, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 26, 2005
Generic low molecular weight heparins: a significant dilemmaJawed Fareed, Omer Iqbal, Helena Nader, et al.
Seminars in Thrombosis and Hemostasis|April 16, 2004
Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosisJawed Fareed, Qing Ma, Michelle Florian, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|April 26, 2007
Potential thrombogenic complications with the use of recombinant activated factor VII in combat traumaJawed Fareed, Rodger L Bick, Craig Kessler, et al.
Expert Opinion on Investigational Drugs|February 28, 2002
Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agentJeanine M Walenga, Walter P Jeske, M Michel Samama, et al.
Seminars in Thrombosis and Hemostasis|January 5, 2005
Generic low-molecular-weight heparins: some practical considerationsJawed Fareed, Wendy L Leong, Debra A Hoppensteadt, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 9, 2006
Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implicationsJyothi Maddineni, Jeanine M Walenga, Walter P Jeske, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 10, 2008
The immunogenic potential of generic version of low-molecular-weight heparins may not be the same as the branded productsJawed Fareed, Rodger L Bick, Gundu Rao, et al.
Pageof 5